Gastrointestinal Cancer | Specialty

Klaus Hoeflich on Treatment Challenges With Liver Cancer

September 10th 2016

Klaus Hoeflich, PhD, director of Biology, Blueprint Medicines, discusses diagnosis of liver cancer as well as the treatment challenges associated with the disease during the 10th Annual Conference of the International Liver Cancer Association in Vancouver, Canada.

Liver Cancer Experts Mark a Decade of Milestones in HCC

September 10th 2016

Although it has been nearly 10 years since a new drug was approved for the treatment of patients with hepatocellular carcinoma, the past decade has been marked by advances on the scientific and radiology fronts and the prospects for the development of new therapies are bright.

Prognostic Tool for Immuno Age Debuts

September 6th 2016

An assay that would evaluate the immune status of patients with colon cancer is poised to become the first of a series of Immunoscore tests for various tumor types.

Obesity an Increasing Incidence in Breast Cancer, CRC Survivors

September 3rd 2016

Obesity is more prevalent in cancer survivors, specifically in those with a history of breast or colorectal cancer, compared with those without any history of disease.

CRC Biomarkers Exert Growing Influence on Prognosis and Treatment

September 2nd 2016

Molecular testing for colorectal cancer continues to evolve at a rapid pace. Biomarkers already have the potential to predict outcomes and better target therapies, with the eventual goal to completely personalize treatments based on the patient’s individual biomarker profile and other tumor markers.

Dr. Sharma on Tolerability of SIRT in Patients With CRC

September 1st 2016

Dr. Navesh K. Sharma, associate professor of Radiology in the Division of Radiology and Oncology at Penn State Hershey Medical Center and section chief of Radiation Oncology at the Penn State Health St. Joseph Cancer Center, discusses the safety profile of selective internal radiation therapy (SIRT) when added to chemotherapy for patients with colorectal cancer (CRC) that has metastasized to the liver.

Multiple Subgroups Needed to Properly Treat Patients With GEJ Cancers

August 30th 2016

Richard J. Bold, MD, discusses the reasoning to break gastroesophageal junction cancers into multiple subgroups and why it is important for treatment and surgical decisions.

Marshall Discusses Role of Regorafenib in Second-Line mCRC Care

August 29th 2016

John L. Marshall, MD, discusses second-line treatment options for patients with metastatic colorectal cancer, along with who is most appropriate to receive regorafenib (Stivarga) and how to manage doses and toxicities when using the multikinase inhibitor.

Expert Highlights Potential of Immunotherapy in Gastric Cancer

August 29th 2016

Zev Wainberg, MD, discusses a plethora of immunotherapy agents, such as pembrolizumab (Keytruda), durvalumab, avelumab, and apatinib, for the treatment of patients with gastric cancer, as well as a number of ongoing clinical trials in this space.

Study Calls for Interventions to Increase Colorectal Cancer Screening in Hispanic Men

August 28th 2016

Colorectal cancer mortality rates have been on the decline in California for both men and women since the mid-1990s, but for one group—Hispanic men—rates have remained essentially unchanged, and a new study suggests that lower rates of screening may be the chief driver of this disparity.

Dr. Matthew Yurgelun on Next Steps in Understanding CRC Mutations

August 26th 2016

Dr. Heinemann on Using Depth of Response in Pretreated Patients With CRC

August 22nd 2016

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses using depth of response as an appropriate endpoint in studies examining patients with metastatic colorectal cancer (mCRC).

Dr. Michael J. Overman on Immunotherapy in Colorectal Cancer

August 19th 2016

Dr. Paty on Patients With Rectal Cancer Ineligible for "Watch and Wait"

August 17th 2016

Philip B. Paty, MD, surgeon, Memorial Sloan Kettering Cancer Center, discusses patients with rectal cancer who are ineligible for a "watch and wait" approach with their surgeons.

Dr. Filippo Pietrantonio on Using Nomogram for Patient Selection in CRC Trials

August 11th 2016

Colorectal Cancer: Patient Follow-Up with Trifluridine/Tipiracil

August 10th 2016

Colorectal Cancer: Patient Follow-Up with Regorafenib

August 10th 2016

Regorafenib in Colorectal Cancer: Optimizing the Dose

August 10th 2016

Practical Advice for Using Trifluridine/Tipiracil

August 10th 2016

Practical Advice for Using Regorafenib

August 10th 2016